Algernon Pharmaceuticals (CSE: AGN – OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news the company has reached 70% enrolment for its Phase 2 clinical study of its re-purposed drug Ifenprodil for idiopathic pulmonary fibrosis and chronic cough.
Moreau telling Proactive, the trial is taking parts at six sites in total with four located in Australia and two in New Zealand. The trial lasts 12 weeks total for patients.